{
    "info": {
        "nct_id": "NCT05023655",
        "official_title": "A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation",
        "inclusion_criteria": "* Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol.\n* Histologically and/or cytologically confirmed advanced or metastatic solid tumor harboring ARID1A mutation (except epithelioid sarcoma)\n* Progression of disease following approved therapies or for which no standard therapy exists\n* For subjects who have experienced any clinically significant toxicity related to a prior anticancer treatment (i.e., chemotherapy, immunotherapy, and/or radiotherapy): at the time the subject provides voluntary written informed consent, all toxicities have either resolved to grade 1 per NCI CTCAE Version 5.0 [11] OR are clinically stable and no longer clinically significant.\n* Have measurable disease as defined by RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Males or females are >18 years of age at the time of providing voluntary written informed consent.\n* Life expectancy >3 months before enrollment.\n* Time between prior anticancer therapy and first dose of tazemetostat as follows:\n\nCytotoxic chemotherapy - At least 21 days Noncytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days. Nitrosoureas - At least 6 weeks. Monoclonal antibody - At least 28 days. Radiotherapy - At least 14 days. In addition, at least 6 weeks from prior radioisotope therapy; and at least 12 weeks from 50% pelvic or total body irradiation.\n\n* Adequate renal function: Creatinine < 2.0 or calculated creatinine clearance ≥ 35 mL/minute per the Cockcroft and Gault formula\n* Adequate bone marrow function:\n\nANC ≥ 750mm3 without growth factor support (filgrastim or pegfilgrastim) for at least 14 days.\n\nPlatelets ≥ 75,000mm3 (≥75 × 109/L) evaluated at least 7 days after platelet transfusion.\n\nHemoglobin ≥9.0 g/dL and may receive transfusion Adequate liver function: Total bilirubin <1.5 × the upper limit of normal (ULN) (except for unconjugated hyperbilirubinemia of Gilbert's syndrome); Alkaline phosphatase (ALP) (in the absence of bone disease), ALT, and AST <3 × ULN (or <5 × ULN if subject has liver metastases).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subjects with epithelioid sarcoma are excluded.\n* Has a prior history of T-Cell Lymphoblastic Lymphoma, T-Cell Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Neoplasm.\n* Female subjects who are pregnant or breastfeeding.\n* Prior exposure to tazemetostat or other inhibitor(s) of EZH2.\n* Subjects with uncontrolled CNS metastases requiring steroids.\n* Subjects taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)\n* Are unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from their diet.\n* Major surgery within 4 weeks before the first dose of study drug. NOTE: Minor surgery (e.g., minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 1 week prior to enrollment.\n* Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat.\n* Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II (Appendix 3), uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia.\n* Have an active infection requiring systemic therapy.\n* Known hypersensitivity to any component of tazemetostat.\n* Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study OR interfere with their ability to receive study treatment or complete the study.\n* Subjects who have undergone a solid organ transplant.\n* Prior malignancy in the past 5 years.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cytotoxic chemotherapy - At least 21 days Noncytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days. Nitrosoureas - At least 6 weeks. Monoclonal antibody - At least 28 days. Radiotherapy - At least 14 days. In addition, at least 6 weeks from prior radioisotope therapy; and at least 12 weeks from 50% pelvic or total body irradiation.",
            "criterions": [
                {
                    "exact_snippets": "Cytotoxic chemotherapy - At least 21 days",
                    "criterion": "cytotoxic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Noncytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days",
                    "criterion": "noncytotoxic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Nitrosoureas - At least 6 weeks",
                    "criterion": "nitrosoureas",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Monoclonal antibody - At least 28 days",
                    "criterion": "monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiotherapy - At least 14 days",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 6 weeks from prior radioisotope therapy",
                    "criterion": "radioisotope therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 12 weeks from 50% pelvic or total body irradiation",
                    "criterion": "50% pelvic or total body irradiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have measurable disease as defined by RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Have measurable disease as defined by RECIST 1.1.",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For subjects who have experienced any clinically significant toxicity related to a prior anticancer treatment (i.e., chemotherapy, immunotherapy, and/or radiotherapy): at the time the subject provides voluntary written informed consent, all toxicities have either resolved to grade 1 per NCI CTCAE Version 5.0 [11] OR are clinically stable and no longer clinically significant.",
            "criterions": [
                {
                    "exact_snippets": "subjects who have experienced any clinically significant toxicity related to a prior anticancer treatment",
                    "criterion": "clinically significant toxicity related to prior anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of toxicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at the time the subject provides voluntary written informed consent, all toxicities have either resolved to grade 1 per NCI CTCAE Version 5.0",
                    "criterion": "toxicity grade (per NCI CTCAE v5.0)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at the time the subject provides voluntary written informed consent, all toxicities ... are clinically stable and no longer clinically significant",
                    "criterion": "toxicity clinical stability and significance",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol.",
            "criterions": [
                {
                    "exact_snippets": "voluntarily agreed to provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "demonstrated willingness and ability to comply with all aspects of the protocol",
                    "criterion": "protocol compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically and/or cytologically confirmed advanced or metastatic solid tumor harboring ARID1A mutation (except epithelioid sarcoma)",
            "criterions": [
                {
                    "exact_snippets": "Histologically and/or cytologically confirmed advanced or metastatic solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "solid tumor harboring ARID1A mutation",
                    "criterion": "ARID1A mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except epithelioid sarcoma",
                    "criterion": "epithelioid sarcoma",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy >3 months before enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy >3 months before enrollment.",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ANC ≥ 750mm3 without growth factor support (filgrastim or pegfilgrastim) for at least 14 days.",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 750mm3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 750,
                                "unit": "mm3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without growth factor support (filgrastim or pegfilgrastim) for at least 14 days",
                    "criterion": "growth factor support (filgrastim or pegfilgrastim)",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration_without_support",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate bone marrow function:",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Time between prior anticancer therapy and first dose of tazemetostat as follows:",
            "criterions": [
                {
                    "exact_snippets": "Time between prior anticancer therapy and first dose of tazemetostat",
                    "criterion": "time interval between prior anticancer therapy and first dose of tazemetostat",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": "specified in subsequent criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression of disease following approved therapies or for which no standard therapy exists",
            "criterions": [
                {
                    "exact_snippets": "Progression of disease following approved therapies",
                    "criterion": "disease progression after approved therapies",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "progression after approved therapies"
                        }
                    ]
                },
                {
                    "exact_snippets": "no standard therapy exists",
                    "criterion": "standard therapy availability",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function: Creatinine < 2.0 or calculated creatinine clearance ≥ 35 mL/minute per the Cockcroft and Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 2.0",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance ≥ 35 mL/minute per the Cockcroft and Gault formula",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "mL/minute"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Males or females are >18 years of age at the time of providing voluntary written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Males or females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": ">18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "providing voluntary written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II (Appendix 3), uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia.",
            "criterions": [
                {
                    "exact_snippets": "history of congestive heart failure greater than New York Heart Association (NYHA) Class II",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arterial hypertension",
                    "criterion": "arterial hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within 6 months of the first dose of study drug",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke within 6 months of the first dose of study drug",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac ventricular arrhythmia",
                    "criterion": "cardiac ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior malignancy in the past 5 years.",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy in the past 5 years.",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since prior malignancy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with uncontrolled CNS metastases requiring steroids.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring steroids",
                    "criterion": "steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects who are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female subjects who are ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects who have undergone a solid organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "Subjects who have undergone a solid organ transplant",
                    "criterion": "solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any component of tazemetostat.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component of tazemetostat",
                    "criterion": "hypersensitivity to any component of tazemetostat",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks before the first dose of study drug. NOTE: Minor surgery (e.g., minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 1 week prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks before the first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "before the first dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "Minor surgery (e.g., minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 1 week prior to enrollment",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat.",
            "criterions": [
                {
                    "exact_snippets": "Are unable to take oral medication",
                    "criterion": "ability to take oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat",
                    "criterion": "uncontrolled gastrointestinal condition that might impair the bioavailability of tazemetostat",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to tazemetostat or other inhibitor(s) of EZH2.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to tazemetostat",
                    "criterion": "tazemetostat exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior exposure to ... other inhibitor(s) of EZH2",
                    "criterion": "EZH2 inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study OR interfere with their ability to receive study treatment or complete the study.",
            "criterions": [
                {
                    "exact_snippets": "Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study",
                    "criterion": "major illness",
                    "requirements": [
                        {
                            "requirement_type": "risk increase to participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other major illness that, in the Investigator's judgment, will ... interfere with their ability to receive study treatment or complete the study.",
                    "criterion": "major illness",
                    "requirements": [
                        {
                            "requirement_type": "interference with ability to receive study treatment or complete the study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)",
            "criterions": [
                {
                    "exact_snippets": "Subjects taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)",
                    "criterion": "medication use (CYP3A4 inducers/inhibitors)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potency",
                            "expected_value": "potent"
                        },
                        {
                            "requirement_type": "CYP3A4 modulation",
                            "expected_value": [
                                "inducer",
                                "inhibitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from their diet.",
            "criterions": [
                {
                    "exact_snippets": "unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from their diet",
                    "criterion": "dietary exclusion of Seville oranges, grapefruit juice, and grapefruit",
                    "requirements": [
                        {
                            "requirement_type": "willingness to exclude",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with epithelioid sarcoma are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with epithelioid sarcoma are excluded.",
                    "criterion": "epithelioid sarcoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Platelets ≥ 75,000mm3 (≥75 × 109/L) evaluated at least 7 days after platelet transfusion.",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 75,000mm3 (≥75 × 10^9/L)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "evaluated at least 7 days after platelet transfusion",
                    "criterion": "time since platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Hemoglobin ≥9.0 g/dL and may receive transfusion Adequate liver function: Total bilirubin <1.5 × the upper limit of normal (ULN) (except for unconjugated hyperbilirubinemia of Gilbert's syndrome); Alkaline phosphatase (ALP) (in the absence of bone disease), ALT, and AST <3 × ULN (or <5 × ULN if subject has liver metastases).",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "may receive transfusion",
                    "criterion": "transfusion",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Total bilirubin <1.5 × the upper limit of normal (ULN) (except for unconjugated hyperbilirinemia of Gilbert's syndrome)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unconjugated hyperbilirubinemia of Gilbert's syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase (ALP) (in the absence of bone disease) ... <3 × ULN",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": "bone disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ... <3 × ULN (or <5 × ULN if subject has liver metastases)",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "ULN"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST <3 × ULN (or <5 × ULN if subject has liver metastases)",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "ULN"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if subject has liver metastases",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Has a prior history of T-Cell Lymphoblastic Lymphoma, T-Cell Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Neoplasm.",
            "criterions": [
                {
                    "exact_snippets": "prior history of T-Cell Lymphoblastic Lymphoma",
                    "criterion": "T-Cell Lymphoblastic Lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of T-Cell Acute Lymphoblastic Leukemia",
                    "criterion": "T-Cell Acute Lymphoblastic Leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of Myelodysplastic Syndrome",
                    "criterion": "Myelodysplastic Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of Acute Myeloid Leukemia",
                    "criterion": "Acute Myeloid Leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of Myeloproliferative Neoplasm",
                    "criterion": "Myeloproliferative Neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}